Dr.Arun Sankaradoss

Scientist C, BRIC-RGCB

Profile

The laboratory currently focuses on developing Nucleic acid-based vaccines for viral infections, with a particular focus on the Dengue virus. Our lab's long-standing research interest is to create an innovative approach to design vaccine antigen libraries for emerging/re-emerging viral threats and their pre-clinical assessment employing new vaccine technologies in conjunction with academic-industry vaccine research collaborative initiatives. We also focus on building a clinical cohort to understand human immune responses to vaccines and natural infections.

Current Focus Areas

  • The current focus of the laboratory is developing next-gen DNA and circRNA-based vaccines for dengue viral infection.

Selected Publications

  • 1. Arun Sankaradoss. (2022). Immune profile and responses of a novel Dengue DNA vaccine encoding EDIII-NS1 consensus design based on Indo-African sequences. Cell Press: Molecular Therapy. 4;30(5):2058-2077

  • 2. Arun Sankaradoss. (2020). Antimicrobial resistance profiling and phylogenetic analysis of Neisseria gonorrhoeae clinical isolates from Kenya in a resource-limited setting. Frontiers in Microbiology. 12:647565.

  • 3. Suraj Jagtap, Chitra Pattabiraman, Arun Sankaradoss, Sudhir Krishna, Rahul Roy . (2022). Evolutionary dynamics of dengue virus in India. Plos Pathogens.

  • 4. Arun Sankaradoss. (2017). Implication of Connexin30 in stemness of glioma: Cx30 reverses malignant phenotype of the glioma by modulating IGF-1R and CD133. Journal of Neuro-Oncology. 152(3):621-622.

  • 5. Arun Sankaradoss. (2016). Connexin 30 downregulates Insulin-like growth factor receptor – 1, abolishes Erk and potentiates effects of an IGF-R inhibitor in a glioma cell line. Brain Research. 1643:80-90

Skills & Proficiency

Nucleic acid vaccine Dengue Antibody dependent enhancement circRNA vaccine Immunology B cells T cells DNA vaccines Viral Infection models Antigen design Immune assays development
View More